INTRODUCTION
============

Patients with chronic kidney disease (CKD) experience a high symptom burden \[[@sfy071-B1]\]. The most commonly reported symptoms in non-dialysis-dependent (NDD)-CKD patients include fatigue, sleep difficulties, muscle weakness, restless legs, pruritus (i.e. itching) and bone/joint pain \[[@sfy071-B1]\]. Our group found that 96% of patients not requiring dialysis reported experiencing at least one symptom \[[@sfy071-B2]\], and the median number of symptoms experienced in those with CKD Stages 3--5 is between five and seven \[[@sfy071-B2], [@sfy071-B3], [@sfy071-B7]\]. This elevated incidence of debilitating symptoms accentuates the reduced health-related quality of life (HRQoL) in this group \[[@sfy071-B7]\], and high symptom burden is associated with increased hospitalization and mortality \[[@sfy071-B10]\].

CKD patients have poor physical functioning \[[@sfy071-B11], [@sfy071-B12]\] and low habitual physical activity levels \[[@sfy071-B13]\]. Both low physical activity \[[@sfy071-B11]\] and poor physical function (PF) \[[@sfy071-B12], [@sfy071-B14]\] are independently associated with adverse outcomes and contribute to the reduction in activities of daily living and quality of life (QoL) in this group. Increased symptom burden \[[@sfy071-B8], [@sfy071-B15]\] may further reduce physical functioning, negatively impacting physical activity levels and intensifying the cycle of poor health \[[@sfy071-B8], [@sfy071-B9], [@sfy071-B11]\]. Accordingly, efforts to alleviate symptom burden in CKD are likely to confer positive benefits on HRQoL and PF. While pharmacological intervention may help relieve some symptoms and consequently arrest HRQoL decline \[[@sfy071-B6], [@sfy071-B8]\], further interventions are necessary to restore and maximize it. The benefits of exercise in CKD are becoming increasingly established with improvements in exercise capacity, PF, strength and clinical outcomes observed \[[@sfy071-B16]\].

Despite the evidence in regard to physiological changes following exercise in CKD, given the significance of self-reported HRQoL and symptom burden, there is a paucity of research on the effects of exercise on these outcomes \[[@sfy071-B20]\]. We investigated the effects of 12 weeks of supervised exercise on self-reported symptom burden, fatigue, HRQoL and physical activity in CKD patients not requiring dialysis. We hypothesized that exercise would have favourable effects on symptom experience, fatigue, HRQoL and physical activity (as a result of improved symptoms and physiological factors).

MATERIALS AND METHODS
=====================

Participants
------------

This was a secondary analysis of data from the 'ExTra CKD' study \[[@sfy071-B17]\] (ISRCTN 36489137) conducted at the University Hospitals of Leicester National Health Service (NHS) Trust between December 2013 and October 2016. Patients gave written informed consent and National Ethical approval was obtained. The study was conducted in accordance with the Declaration of Helsinki. Eligible participants were: (i) diagnosed with moderately severe CKD (Stages 3b--5); (ii) aged ≥18 years; and (iii) free of physical impairment and comorbidities that were a contraindication to exercise \[e.g. unstable hypertension, potentially lethal arrhythmia, uncontrolled diabetes mellitus (glycated hemoglobin (HbA1c) \>9%)\].

Exercise intervention
---------------------

Full study methodology is described elsewhere \[[@sfy071-B17]\]. In summary, patients attended the research gym three times a week for 12 weeks. Patients were randomized \[stratified for estimated glomerular filtration rate (eGFR)\] into one of the two supervised exercise groups: aerobic exercise (AE): ∼70--80% of maximum heart rate, 30 min duration on each session, performed on standard cardiovascular equipment (e.g. treadmill);a combination (CE) of AE (as above but for 20 min duration on two sessions, 30 min AE only for the remaining session), plus resistance training (∼70% one repetition maximum, three sets of 8--12 repetitions) on a leg extension and leg press machine, on two sessions where 20 min AE was completed.

Outcome measures
----------------

To negotiate the absence of a control group, prior to randomization, patients underwent a 6-week control period. All self-reported outcomes reported below were completed by patients in their own time prior to attendance at baseline or post-intervention physiological assessments. Questionnaires returned were screened for missing data and highlighted to the patient in person. Patients were reminded to return questionnaires if they had not done so already.

Symptom burden
--------------

### Leicester Uraemic Symptom Scale

The 11-item Leicester Uraemic Symptom Scale (LUSS) \[[@sfy071-B21], [@sfy071-B22]\] evaluated the number, frequency (0 = 'never' to 4 = 'every day') and intrusiveness (symptom impact) (0 = 'not at all intrusive' to 4 = 'extremely intrusive') of uraemic symptoms. Each individual symptom was scored out of four, and summative scores were generated: Total symptom number (LUSS-1): total number of symptoms experienced (out of 11).Total symptom frequency score (LUSS-2): frequency of each 11 symptoms rated 0--4 (out of 44).Total symptom intrusiveness score (LUSS-3): perceived intrusiveness of each 11 symptoms rated 0--4 (out of 44).

The LUSS has been widely used to determine symptom burden in renal populations \[[@sfy071-B7], [@sfy071-B12], [@sfy071-B19], [@sfy071-B21]\] and has recently been validated by our group \[[@sfy071-B22]\].

### Functional Assessment of Chronic Illness Therapy-Fatigue Scale

The validated Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) assessed fatigue and its impact on daily activities. It uses a 5-point Likert scale (0 = 'not at all' to 4 = 'very much') based on a 7-day recall period. Different fatigue domains were measured (e.g. 'physical', 'social/family', 'functional' well-being, plus 'additional concerns'). These were combined to form summative scores: FACT-G: sum of subscale scores (out of 108);Trial Outcome Index (TOI): sum of the 'physical' and 'functional' well-being and 'additional concerns' subscales. The TOI is regarded as an efficient index of physical/functional outcomes and used as a common endpoint in clinical trials (out of 108);total FACIT-F score: sum of all domains (out of 160).

In all scales, a higher score denoted lower fatigue. Subscale scores were deemed acceptable when ≥50% of items were answered and summative scores when response rate was ≥80% \[[@sfy071-B23]\].

Quality of life and PF
----------------------

### EuroQol Five Dimensions (five-level scale)

The EuroQol Five Dimensions (five-level scale) (EQ-5D-5L) is a well-established generic instrument for assessing HRQoL \[[@sfy071-B24]\]. Patients classified their state of health by selecting one of the five different levels (1 = 'none', 2 = 'slight'; 3 = 'moderate'; 4 = 'severe'; and 5 = 'unable') of problem severity within each health domain (mobility, capacity for self-care, conduct of usual activities, pain/discomfort, anxiety/depression). Scores were converted into a single index value (scored +1.0 to −0.594, where a higher score denoted better QoL). The EQ-5D-5L included a visual analogue scale (VAS) indicating current health status on a scale between 0 (worst) and 100 (best).

### Medical outcomes 36-Item Short Form Survey

The 36-Item Short Form Survey (SF-36) is a measure of functioning and well-being \[[@sfy071-B25]\] that is validated among the general population and numerous disease populations including kidney disease \[[@sfy071-B5], [@sfy071-B26], [@sfy071-B27]\]. The SF-36 measures eight dimensions: PF, role limitations caused by physical problems (RP), pain (BP), general health (GH), vitality/energy (VT), social function (SF), mental health (MH)/emotional well-being and role limitations caused by emotional problems/MH (RE). For each parameter, scores were transformed from 0 to 100, with higher scores indicating better health. Summary physical and mental component scores were calculated \[[@sfy071-B27]\]. The modified SF-36 (v 1.0) was used. Norm reference population (aged 60--64 years) scores are: PF = 69.6; RP = 70.1; BP = 62.3; GH = 60.9; VT = 55.6; SF= 76.9; RE = 84.9; MH = 74.1 \[[@sfy071-B28]\].

### Duke Activity Status Index

Validated in patients with CKD \[[@sfy071-B29]\], the Duke Activity Status Index (DASI) was used to evaluate functional capacity. The DASI queried patients, 'yes' or 'no', whether they could complete a range of physical activities. Each question or activity was assigned a value based on the estimated peak oxygen uptake \[metabolic equivalent (MET)\]. 'Yes' responses were summed to give a raw DASI score (0--58.2). Higher scores indicated higher functional capacity.

Physical activity
-----------------

### Godin--Shephard Leisure Time Exercise Questionnaire

The Godin--Shephard Leisure Time Exercise Questionnaire (GSLTEQ) was used to determine physical activity levels \[[@sfy071-B30]\]. Activities were classified into three subgroups \['strenuous' (nine METs), 'moderate' (five METs), 'light' (three METs)\]. The frequency and type of activities or exercises performed weekly were used to calculate the total score (METs × times/week). A score of ≥24 U was regarded as active; 14--23 U regarded as moderately active; and ≤13 U regarded as inactive \[[@sfy071-B30]\].

### Self-efficacy for Physical Activity Scale

In order to assess whether exercise increased patients' self-efficacy, we used the Self-efficacy for Physical Activity Scale (SEPA), a five-item scale with five-point Likert response levels (1 = 'not at all confident' to 5 = 'extremely confident'). A summary score (1--5) was calculated by averaging responses. Higher scores reflect higher levels of self-efficacy \[[@sfy071-B31]\]. The SEPA has shown high construct validity with numerous measures of physical activity and is used widely in clinical populations \[[@sfy071-B32]\].

Statistical analysis
--------------------

As a secondary per-protocol analysis of Watson *et al.* \[[@sfy071-B17]\], no *a priori* sample size calculation is provided for the outcomes presented. Data are presented as mean (±SD). The 95% confidence intervals (CIs) were calculated for changes pre- and post-exercise. Significance was recognized as \<0.05. Within-group differences were assessed using paired-samples *t*-tests. Between-group differences were assessed for changes pre- and post-exercise using linear regression modelling. Age, group, sex, eGFR and baseline values for that variable were used as covariants, and the presence of a significant group coefficient indicted a between-group difference. The expectation-maximization (EM) algorithm was used to impute missing questionnaire data (see [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S1](#sup1){ref-type="supplementary-material"}) and to restore adequate sample size for each outcome (*n *=* *18 for both groups). EM is based on two iterating steps (50 iterations were used) that generate means and variances for missing data based on known values for that variable. Categorical data used in EM estimates were age, group, sex and eGFR, with values at pre- and post-exercise used as quantitative variables. Little's missing completely at random (MCAR) test and separate variance *t*-tests confirmed the suitability of using EM. Raw data were evaluated to verify the imputed differences. Statistical guidance was provided by statisticians from the Leicester Biomedical Research Centre Clinical Trials Unit, and data were analysed using SPSS 24 software.

Results
=======

Participants
------------

Thirty-six patients completed the intervention ([Table 1](#sfy071-T1){ref-type="table"}). For brevity, recruitment and retention rates to the study are reported elsewhere \[[@sfy071-B17]\]. Out of 36 available exercise sessions, compliance was good and both groups completed 32 sessions (88%) on average. Table 1.Patient characteristicsVariableAE *(n *=* *18)CE (*n *=* *18)Age (years)63.7 (±8.5)59.6 (±14.4)Sex, female, *n* (%)11 (61)11 (61)BMI (kg/m^2^)30.2 (±5.8)29.4 (±5.8)Ethnicity White British, *n* (%)11 (61)9 (50) White European, *n* (%)2 (11)1 (6) Asian, *n* (%)4 (22)8 (44) Black Caribbean, *n* (%)1 (6)0 (0)Disease aetiology Diabetic nephropathy, *n* (%)2 (11)1 (6) Interstitial nephritis, *n* (%)2 (11)2 (11) IgA nephropathy, *n* (%)2 (11)1 (6) Polycystic kidney disease, *n* (%)0 (0)3 (17) Other, *n* (%)0 (0)2 (11) Unknown/aetiology uncertain, *n* (%)12 (67)9 (50)Comorbidities Diabetes mellitus type II, *n* (%)7 (39)2 (11) Hypertension (essential  or secondary), *n* (%)9 (50)7 (39)Clinical parameters eGFR (mL/min/1.73 m^2^)26.6 (±8.7)(±6.9)  Stage 3b*, n* (%)6 (33)5 (27)  Stage 4, *n* (%)12 (67)12 (67)  Stage 5, *n* (%)0 (0)1 (6) Haemoglobin (mg/dL)123.1 (±14.0)114.4 (±14.1) Albumin (g/L)41.9 (±2.6)39.7 (±2.8) Systolic blood pressure (mmHg)136.2 (±22.0)123.4 (±10.4) Diastolic blood pressure (mmHg)73.7 (±12.5)68.2 (±9.4)[^1]

Outcome measures
----------------

No significant changes were seen in any questionnaire outcome over the 6-week control period (see [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S2](#sup1){ref-type="supplementary-material"}).

Symptom burden
--------------

Changes in symptom burden (frequency and intrusiveness) following exercise can be found in [Tables 2](#sfy071-T2){ref-type="table"} and [3](#sfy071-T3){ref-type="table"}. In the AE group, the total number of symptoms were reduced by 1 (95% CI −2 to 0) from 6 (±3) to 5 (±2) (P* *=* *0.01) (individual changes are shown in [Figure 1](#sfy071-F1){ref-type="fig"}). In regard to individual symptoms, reductions were seen in the frequency of 'itching' (P* *=* *0.01), 'impotence' (P* *=* *0.03) and 'shortness of breath' (P* *=* *0.03), as well as a total symptom frequency score (P* *=* *0.01). Following exercise, the AE group reported less intrusiveness for symptoms of 'sleep disturbance', 'loss of muscular strength/power', 'muscle spasm/stiffness' and 'restless legs' (P's = 0.01--0.03), and as such, the total symptom intrusiveness score also reduced (P* *=* *0.01). Table 2.Symptom burden (frequency) changes pre- and post-exerciseFrequency of symptomsAE (*n *=* *18)CE (*n *=* *18)P-value[^a^](#tblfn3){ref-type="table-fn"}PrePostChange (95% CI)P-valuePrePostChange (95% CI)P-valueItching (0--4)**2.0 (±1.3)1.2 (±1.1)−0.7 (−1.2 to −0.3)0.01\***1.6 (**±**1.0)1.6 (**±**1.2)**−**0.0 (**−**0.7 to 0.6)0.88**0.04\***Sleep disturbance (0--4)2.0 (**±**0.9)2.0 (**±**0.7)0.0 (**−**0.3 to 2.2)0.731.8 (**±**1.4)1.8 (**±**1.4)0.0 (**−**0.2 to 0.2)0.90.68Loss of appetite (0--4)0.4 (**±**0.4)0.5 (**±**0.7)+0.1 (**−**0.3 to 0.4)0.750.9 (**±**0.9)0.7 (**±**1.0)**−**0.2 (**−**0.8 to 0.4)0.470.53Excessive tiredness (0--4)1.3 (**±**1.0)1.3 (**±**0.7)0.0 (**−**0.3 to 0.4)0.761.9 (**±**1.3)1.7 (**±**1.3)**−**0.3 (**−**0.6 to 0.1)0.110.15Pain in bones/joints1.3 (**±**1.2)1.4 (**±**1.3)+0.1 (**−**0.2 to 0.3)0.48**1.3 (±1.0)1.7 (±1.3)+0.4 (0.0 to 0.9)0.05\***0.19Poor concentration (0--4)0.5 (**±**0.6)0.8 (**±**0.9)+0.3 (**−**0.1 to 0.7)0.090.6 (**±**0.6)1.1 (**±**1.1)+0.5 (**−**0.2 to 1.1)0.150.48Impotence/lack of sex drive (0--4)**1.3 (±1.2)1.0 (±1.3)−0.3 (−0.6 to 0.0)0.03\***1.6 (**±**1.4)1.6 (**±**1.7)0.0 (**−**0.2 to 0.2)0.83**0.03\***Loss of muscular strength/ power (0--4)1.0 (**±**0.9)0.8 (**±**1.1)**−**0.2 (**−**0.6 to 0.2)0.31**1.7 (±1.0)0.9 (±1.1)−0.7 (−1.1 to −0.4)0.01\***0.07Shortness of breath (0--4)**1.5 (±1.3)0.9 (±1.1)−0.6 (−1.2 to −0.1)0.03\***1.6 (**±**1.0)1.1 (**±**1.1)**−**0.5 (**−**1.0 to 0.0)0.050.61Muscle spasm/stiffness (0--4)1.2 (**±**1.0)0.9 (**±**1.0)**−**0.2 (**−**0.6 to 0.2)0.261.1 (**±**0.9)1.0 (**±**1.2)**−**0.1 (**−**0.5 to 0.4)0.780.48Restless legs (0--4)0.8 (**±**1.1)0.5 (**±**0.7)**−**0.3 (**−**0.8 to 0.2)0.270.9 (**±**0.9)0.6 (**±**1.1)**−**0.3 (**−**0.7 to 0.1)0.140.88Total frequency (LUSS-2) (0--44)**13.0 (±6.7)10.6 (±5.6)−2.3 (−3.7 to −1.0)0.01\***14.8 (**±**7.0)13.4 (**±**9.6)**−**1.3 (**−**3.2 to 0.7)0.190.16[^2][^3]Table 3.Symptom burden (intrusiveness) changes pre- and post-exerciseIntrusiveness of symptomsAE (*n *=* *18)CE (*n *=* *18)P-value[^a^](#tblfn5){ref-type="table-fn"}PrePostChange (95% CI)P-valuePrePostChange (95% CI)P-valueItching (0--4)1.6 (**±**1.2)1.4 (**±**1.1)−0.2 (−0.6 to 0.2)0.321.3 (**±**1.0)1.4 (**±**1.0)+0.1 (−0.3 to 0.6)0.470.13Sleep disturbance (0--4)**2.2 (±0.9)1.8 (±0.9)**−**0.3 (**−**0.5 to 0.2)0.01\***2.2 (**±**1.5)2.1 (**±**1.7)−0.1 (−0.4 to 0.1)0.38**0.04\***Loss of appetite (0--4)0.6 (**±**0.5)0.6 (**±**0.5)0.0 (−0.2 to 0.1)0.760.9 (**±**0.9)0.9 (**±**0.9)0.0 (−0.3 to 0.4)0.820.55Excessive tiredness (0--4)1.8 (**±**1.1)1.8 (**±**0.8)0.0 (−0.3 to 0.4)0.712.4 (**±**1.6)2.1 (**±**1.4)−0.3 (−0.7 to 0.2)0.210.29Pain in bones/joints (0--4)1.6 (**±**1.2)1.6 (**±**1.1)0.0 (−0.2 to 0.2)0.91.5 (**±**1.2)1.8 (**±**1.4)+0.3 (−0.1 to 0.7)0.160.22Poor concentration (0--4)1.0 (**±**0.9)1.0 (**±**0.8)0.0 (−0.2 to 0.2)0.891.4 (**±**1.0)1.2 (**±**1.1)−0.2 (−0.5 to 0.1)0.180.62Impotence/lack of sex drive (0--4)1.2 (**±**1.4)0.9 (**±**1.3)−0.3 (−0.7 to 0.1)0.131.4 (**±**1.2)1.4 (**±**1.7)+0.1 (−0.7 to 0.7)0.800.39Loss of muscular strength/ power (0--4)**1.4 (±1.0)1.0 (±0.9)**−**0.3 (**−**0.6 to 0.0)0.03\*1.8 (±0.9)1.1 (±1.1)**−**0.7 (**−**1.1 to** −**0.4)\<0.001\***0.06Shortness of breath (0--4)1.2 (**±**1.0)1.0 (**±**0.9)−0.2 (−0.6 to 0.2)0.32**1.7 (±1.3)1.1 (±1.2)**−**0.6 (**−**1.0 to** −**0.2)0.01\***0.27Muscle spasm/stiffness (0--4)**1.7 (±1.2)1.2 (±1.1)**−**0.5 (**−**0.8 to 0.1)0.02\*1.3 (±0.9)1.1 (±1.1)**−**0.2 (**−**0.5 to 0.0)0.04\***0.17Restless legs (0--4)**1.1 (±1.0)0.7 (±0.9)**−**0.3 (**−**0.6 to** −**0.1)0.01\*1.0 (±0.9)0.7 (±1.0)**−**0.2 (**−**0.4 to 0.0)0.05\***0.29Total intrusiveness (LUSS-3) (0--44)**14.7 (±8.0)12.2 (±5.9)**−**2.5 (**−**4.2** to −**0.8)0.01\*17.3 (±7.7)14.0 (±10.6)**−**3.3 (**−**5.3** to − **1.3)0.01\***0.9[^4][^5]

![Individual changes in the number of symptoms reported pre- and post-exercise from the LUSS. Data show the reduction (or increase) in the number of symptoms for each of the 18 individual patients in each group.](sfy071f1){#sfy071-F1}

In the CE group, a reduction in 'loss of muscular strength/power' (P* *=* *0.01) was observed, as well as reports of less intrusiveness for 'loss of muscular strength/power', 'shortness of breath', 'muscle spasm/stiffness' and 'restless legs' (Ps \< 0.001--0.05). Total symptom intrusiveness score was reduced (P* *=* *0.01). Conversely, an increase in the frequency of 'joint/bone pain' symptoms was observed (P* *=* *0.05). No significant change in the number of symptoms was seen \[7 (±3) to 6 (±3), P* *=* *0.1\] although the number (--1) was comparable to the AE.

Fatigue changes are reported in [Table 4](#sfy071-T4){ref-type="table"}. Exercise had favourable effects on the FACT-G (AE: P* *=* *0.01, CE: P* *=* *0.05), TOI (P* *=* *0.01 in both groups) and total FACIT-F scores (P* *=* *0.01 in both groups). No significant between-group differences were seen. Table 4.Changes pre- and post-exercise in the FACIT-FComponentAE (*n *=* *18)CE (*n *=* *18)Between-groupMean (±SD)P-valueMean (±SD)P-valueP-value[^a^](#tblfn6){ref-type="table-fn"}FACT-G Pre84.3 (±15.0)75.9 (±14.8) Post91.6 (±7.9)81.5 (±13.5) Change (95% CI)**+7.3 (3.0 to 11.7)0.01\***+5.7 (−0.2 to 11.3)0.050.05TOI Pre82.0 (±17.7)65.9 (±24.7) Post89.9 (±10.8)80.0 (±16.4) Change (95% CI)**+7.9 (**−**2.9 to 12.9)0.01\*+14.0 (**−**6.5 to 21.4)0.01\***0.81Total FACIT-F Pre122.9 (±21.1)103.2 (±27.9) Post134.7 (±11.9)119.4 (±20.0) Change (95% CI)**+11.8 (5.6 to 17.6)0.01\*+16.2 (7.3 to 24.0)0.01\***0.26[^6]

HRQoL and PF
------------

No changes were seen in the EQ-5D-5L index in either group \[AE: 0.84 (±0.18) to 0.85 (±0.16), P* *=* *0.7; CE: 0.87 (±0.12) to 0.87 (±0.15), P* *=* *0.9; between-group difference P* *=* *0.8\]. An increase in the EQ-5D-5L VAS was seen in the AE group \[70.2 (±17.2) to 75.2 (±14.9), P* *=* *0.04\] although no change was observed in the CE group \[67.2 (±15.3) to 69.6 (±17.0), P* *=* *0.40; between-group difference P* *=* *0.34\].

Changes in the SF-36 are shown in [Table 5](#sfy071-T5){ref-type="table"}. Although no significant changes were observed, improvements in 'Role Physical' score \[+12.4 (--1.8 to 26.6)\] in the CE group, and the 'Vitality' score \[+6.9 (--5.1 to 18.8)\] in the AE group exceeded the minimal clinical important difference (MCID) (+5 points) \[[@sfy071-B33]\]. No changes were seen in the DASI \[AE: 40.8 (±13.8) to 39.9 (±17.5), P* *=* *0.72; CE: 40.5 (±10.4) to 40.6 (±13.8), P* *=* *0.9; between-group difference P* *=* *0.9\]. Table 5.Changes pre- and post-exercise in the medical outcomes SF-36ComponentAE (*n *=* *18)CE (*n *=* *18)Between-groupMean (±SD)P-valueMean (±SD)P-valueP-value[^a^](#tblfn7){ref-type="table-fn"}PF Pre78.1 (±21.5)72.5 (±30.0) Post80.2 (±20.8)70.3 (±30.0) Change (95% CI)+2.1 (−1.2 to 5.3)0.21−2.3 (−10.0 to 5.5)0.550.09RP Pre74.5 (±34.8)57.8 (±36.4) Post78.2 (±37.6)70.2 (±31.1) Change (95% CI)+3.6 (−9.9 to 17.2)0.58+12.4 (−1.8 to 26.6)0.080.83BP Pre72.7 (±26.4)71.2 (±15.8) Post75.2 (±22.4)68.0 (±17.7) Change (95% CI)+2.5 (−6.9 to 11.9)0.59−3.3 (−11.0 to 4.5)0.390.17GH Pre59.2 (±19.6)50.1 (±16.7) Post62.7 (±15.9)53.7 (±17.9) Change (95% CI)+3.5 (−3.5 to 10.4)0.31+3.6 (−0.9 to 8.1)0.110.78VT Pre62.0 (±28.3)58.7 (±16.6) Post68.9 (±19.4)62.4 (±15.3) Change (95% CI)+6.9 (−5.1 to 18.8)0.24+3.8 (−3.9 to 11.4)0.310.20SF Pre86.2 (±29.2)88.8 (±14.0) Post88.6 (±17.9)89.3 (±11.1) Change (95% CI)+2.4 (−11.0 to 7.8)0.710.5 (−6.8 to 7.8)0.890.80RE Pre82.4 (±34.6)85.8 (±20.0) Post85.3 (±33.0)85.9 (±25.0) Change (95% CI)+2.9 (−6.7 to 12.6)0.53+0.1 (−15.0 to 15.2)0.90.81MH Pre84.2 (±16.5)80.3 (±10.3) Post87.6 (±7.9)79.4 (±18.8) Change (95% CI)+3.3 (−5.4 to 12.1)0.43−1.0 (−10.2 to 8.3)0.830.17PCS Pre47.0 (±8.8)43.0 (±7.9) Post47.0 (±8.7)44.1 (±9.1) Change (95% CI)+0.8 (−0.9 to 2.5)0.35+1.1 (−0.2 to 2.4)0.090.84MCS Pre54.0 (±9.1)54.3 (±5.0) Post55.7 (±6.2)54.5 (±8.5) Change (95% CI)+1.7 (−2.9 to 6.5)0.44+0.2 (−3.8 to 4.2)0.90.67[^7]

Physical activity
-----------------

Self-reported GSLTEQ physical activity scores were not changed \[AE: 25.6 (±22.0) to 27.7 (±19.0), P* *=* *0.45; CE: 26.2 (±20.5) to 22.2 (±13.3), P* *=* *0.26, although the between-group difference was significant, P* *=* *0.02\]. Self-efficacy increased significantly in the AE group \[2.5 (±1.4) to 3.1 (±0.9), P* *=* *0.03\] although no change was seen in the CE group \[2.6 (±0.8) to 2.8 (±0.8), P* *=* *0.57; between-group difference P* *=* *0.17\].

Discussion
==========

In CKD patients, 12 weeks of supervised exercise had favourable effects on symptom frequency and intrusiveness, including improvements in fatigue-related outcomes. Although exercise did not improve self-reported physical activity levels, it did increase self-efficacy for physical activity. This secondary analysis supplements the improvements in physical performance and the strength reported in Watson *et al.* \[[@sfy071-B17]\] and supports the necessary role of exercise in CKD.

Regardless of the exercise modality, we found beneficial effects on symptom burden with the number of symptoms falling from 6 to 5; a reduction of 17%. Kosmadakis *et al.* \[[@sfy071-B19]\] also reported a decline in symptom frequency on the LUSS following 6 months walking (30 min, five times a week) in 40 CKD patients. In the AE group, reductions in the frequency of 'itching' (by 35%) and 'shortness of breath' symptoms (by 40%) were observed. Although these symptoms are frequently reported in CKD \[[@sfy071-B2], [@sfy071-B3], [@sfy071-B8]\], there is a scarcity of research into the effect of exercise on them. Although preliminary data showed a reduction in itching after intradialytic cycling \[[@sfy071-B34]\], further investigation is needed to elucidate the potential mechanisms behind this. Unsurprisingly, given the well-established benefits of exercise on aerobic capacity \[[@sfy071-B16]\], we observed a reduction in dyspnoea (i.e. 'shortness of breath'). In support of this, our original trial \[[@sfy071-B17]\] reported an increase in peak oxygen uptake.

The AE group reported less intrusiveness for 'sleep disturbance' and a reduced total symptom intrusiveness score. Difficulties in sleep duration and quality are common in CKD and can have substantial impact on QoL. While research is limited in NDD-CKD, positive effects of exercise on sleep quality in renal transplant recipients \[[@sfy071-B35]\] and older adults \[[@sfy071-B36]\] have been shown. Possible mechanisms are complex and beyond the scope of this article; however, increased energy consumption, endorphin secretion and diurnal rhythm have been cited \[[@sfy071-B35], [@sfy071-B36]\].

The addition of resistance training (CE group) resulted a reduction in the number of 'loss of muscular strength/power' symptoms by 41%. Concurrently, we observed significant improvements in muscle mass and strength in Watson *et al.* \[[@sfy071-B17]\], and this appears to have resulted in reductions in perceived weakness. This supports our recommendation that resistance training should form an integral part of exercise guidelines in CKD as skeletal muscle wasting and resultant loss of muscle function are common \[[@sfy071-B15], [@sfy071-B37]\]. It should be noted that the CE group reported an increase in the frequency of 'joint/bone pain' symptoms; whether this is a result of performing additional resistance-based training is unknown. Resistance training in CKD should be carefully progressed at a rate concomitant with patient ability and adequate recovery should be observed. As the CE group also completed an AE component, they too reported reductions in 'shortness of breath' symptom intrusiveness.

Both groups reported less intrusiveness for 'loss of muscular strength/power' and 'muscle spasm/stiffness' symptoms. This could be the result of the increased strength and PF observed \[[@sfy071-B17]\]. Improvements in perceived muscle stiffness could be a consequence of general exercise-induced reductions in pain or inflammation, or improvements in range of motion and/or muscle architecture. Both groups reported less intrusiveness of 'restless legs' symptoms. Common in CKD, particularly in advanced disease stages, restless legs syndrome (RLS) is a sensorimotor disorder characterized by an uncontrolled urge to move the affected body parts \[[@sfy071-B38]\]. Interestingly, exercise (both AE and CE) has been proved effective in improving RLS in both healthy middle-aged men \[[@sfy071-B39]\] and in haemodialysis patients \[[@sfy071-B38]\]. Symptoms are reportedly alleviated, at least temporarily, by physical activity \[[@sfy071-B39]\], with a potential effect from endorphin release \[[@sfy071-B40]\].

Exercise had large positive effects on fatigue symptoms in both groups. Symptoms of fatigue are consistently reported in CKD \[[@sfy071-B1], [@sfy071-B2], [@sfy071-B8], [@sfy071-B41]\]. With up to 80% of patients suffering from fatigue \[[@sfy071-B4]\], it is a key barrier to regular participation in physical activity/exercise \[[@sfy071-B8]\]. Although research is limited in renal populations, exercise is an effective intervention in reducing fatigue, especially in cancer patients \[[@sfy071-B42]\]. Although the mechanisms are likely to be multi-factorial, it appears that improvements in aerobic/exercise/functional capacity and strength, as observed in our trial \[[@sfy071-B17]\], resulted in reduced effort and improvement in the perception of fatigue during activities of daily living \[[@sfy071-B42]\]. Fatigue in CKD has also been associated with poor sleep quality, RLS, excessive daytime sleepiness and low albumin levels \[[@sfy071-B41]\]. Consequently, our improvements in sleep disturbance, restless legs, muscle weakness and stiffness, and shortness of breath symptoms may translate to reduced perceptions of fatigue.

Although a small change for the EQ-5D-5L VAS was seen in AE group, this did not reach the MCID \[[@sfy071-B43]\], and no changes were seen in the EQ-5D-5L index in either group. Research by Mustata *et al.* \[[@sfy071-B44]\], albeit in 10 CKD patients, found that AE (combined supervised and home-based) was able to elicit a clinically important improvement in the EQ-5D-5L index. However, in this trial, patients were older with greater disease progression and poorer exercise capacity; the baseline EQ-5D-5L index in that trial was 0.77 compared with 0.84--0.87 observed in our patients. Accordingly, our cohort may denote a relatively 'healthy' sample of patients, and our EQ-5D-5L index is highly comparable to the normative value of 0.86 for people aged 55--64 years in the UK \[[@sfy071-B24]\].

The SF-36 values of our sample also suggest a somewhat 'healthy' cohort, and scores for 'PF', 'BP', 'VT', 'SF' and 'MH' were ∼11% above the mean scores for a norm reference population (60--64 years) \[[@sfy071-B28]\]. Although no significant changes were seen as a result of exercise, the 'RP' score (+12.4) in the CE group, and 'VT' score (+6.9) in the AE group exceeded the MCID (+5 points) \[[@sfy071-B33], [@sfy071-B45]\]. Interestingly, Mustata *et al.* \[[@sfy071-B44]\] also reported a clinically important change in the 'RP' domain (i.e. role limitations caused by physical problems \[[@sfy071-B5]\]). The improvements in physical capacity observed in our trial could reduce limitations of daily activities. The 'VT' domain reflects 'energy level' and 'fatigue' \[[@sfy071-B2], [@sfy071-B45]\]. Therefore, improvements in other fatigue outcomes (as described above) are also reflected in increased 'VT'.

Despite significant changes in objective functional capacity \[[@sfy071-B17]\], we observed no changes in the DASI---a subjective measure of physical functioning. Despite its clinical utility, the DASI may not be suitable to differentiate individuals with high functional capacity (as apparent in our trial) due to a 'ceiling effect' \[[@sfy071-B46]\]. This effect exists when ≥15% of the sample reaches the maximal score \[[@sfy071-B47]\]. Indeed, 25% of our total sample reached this 'ceiling' post-exercise.

Self-reported physical activity scores from the GSLTEQ were not changed in both groups. A score of ≥24 U is regarded as 'active' \[[@sfy071-B30]\]. As such, the mean baseline scores in patients recruited (∼26 U) indicate a relatively active cohort, and may explain why physical activity did not increase (i.e. patients reasoned themselves as sufficiently active already). Although physical activity levels did not change, self-efficacy for physical activity increased in the AE group. Self-efficacy, or confidence in one's ability to perform a given behaviour despite obstacles, is a task-specific construct that influences the amount of time and effort individuals are willing to invest in order to overcome barriers \[[@sfy071-B48]\]. Engaging in a supervised exercise intervention has been shown to have favourable effects on self-efficacy \[[@sfy071-B49]\], including following pulmonary rehabilitation \[[@sfy071-B50]\].

As stated elsewhere \[[@sfy071-B17]\], the main limitation regards a lack of a non-exercising control group, which was excluded to promote recruitment to the study. However, we feel that this is somewhat negated by a 6-week control period prior to group allocation. Although we observed no changes in self-reported outcomes during this control period, suggesting the changes we observed are likely to be the result of the exercise intervention, the absence of a control group does not provide assessment on whether changes were driven by non-exercise psychosocial context variables including expectation, conditioning or social interactions. A lack of a 'resistance training only' group also means that we are unable to isolate the effects of this modality.

The questionnaire return rate in this study was poor (across all questionnaires ∼50% had completed pre- and post-intervention data). To that end, we used EM imputation to restore sample size and to provide a more accurate interpretation of any changes. Although the missingness of data was confirmed using Little's MCAR test, we cannot exclude the possibility that patients with a more positive psychosocial response may have been more likely to return the questionnaires post-intervention. We used *t*-tests to investigate differences in age, sex, renal function and pre-intervention scores in patients who had complete and incomplete response rates for outcomes (i.e. the DASI and 'number of symptoms' question from the LUSS) identified as 'missing at random', but no explanatory variables could be identified. The number of missing data in our study highlights the importance by reducing patient outcome measure burden in study design, especially when the patient completes these in their own time. Efforts should be made to reduce the number of self-reported measures, but also ensure efficient management to achieve maximal return rates. Although getting patients to complete self-reported measures in the presence of a researcher may introduce observer bias, it would reduce missing data and improve response rate considerably. This was a secondary analysis of Watson *et al.* \[[@sfy071-B17]\], which was powered to elicit physiological hypertrophic muscle responses. Consequently, the effects of exercise on self-reported outcomes reported here should be interpreted cautiously.

In conclusion, 12 weeks of exercise had favourable effects on symptom frequency and intrusiveness, including improvements in fatigue in CKD patients. These positive changes in self-reported outcomes support the important role of exercise in CKD management. Further research is needed to elucidate upon the physiological and psychological mechanisms of how exercise influences symptoms and other patient-reported outcomes.
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[^1]: Data are presented as mean (±SD), unless otherwise specified. BMI, body mass index; IgA, immunoglobulin A.

[^2]: Data are presented as mean (±SD).

[^3]: Between-group P-value with age, group, sex, eGFR and baseline values for that variable were used as covariants. Values are significant at P* *\<* *0.05 and denoted by \*.

[^4]: Data are presented as mean (±SD).

[^5]: Between-group P-value with age, group, sex, eGFR and baseline values for that variable were used as covariants. Values are significant at P* *\<* *0.05 and denoted by \*.

[^6]: Between-group P-value with age, group, sex, eGFR and baseline values for that variable were used as covariants. Values are significant at P* *\<* *0.05 and denoted by \*.

[^7]: Between-group P-value with age, group, sex, eGFR and baseline values for that variable were used as covariants. Values are significant at P* *\<* *0.05.
